Becton, Dickinson and Company (NYSE:BDX) Stock Price Target Raised at Royal Bank Of Canada

Becton, Dickinson and Company (NYSE:BDX) had its price target lifted by Royal Bank Of Canada from $190.00 to $225.00 in a report published on Friday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the medical instruments supplier’s stock.

BDX has been the topic of a number of other reports. Barclays initiated coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They set an “underweight” rating and a $165.00 price target on the stock. Bank of America raised their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Monday, August 31st. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Weiss Ratings raised Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Finally, Wolfe Research initiated coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $193.67.

Becton, Dickinson and Company Price Performance

NYSE BDX traded down $1.28 during trading on Friday, hitting $212.27. 2,172,550 shares of the company’s stock were exchanged, compared to its average volume of 1,599,485. The stock’s 50 day moving average price is $188.17 and its two-hundred day moving average price is $170.28. The company has a market cap of $58.49 billion, a PE ratio of 51.27, a P/E/G ratio of 13.39 and a beta of 0.22. Becton, Dickinson and Company has a fifty-two week low of $137.35 and a fifty-two week high of $214.88. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. During the same period last year, the company earned $3.96 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Research analysts expect that Becton, Dickinson and Company will post 13.24 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be issued a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase program on Thursday, November 5th that authorizes the company to buy back 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 3.6% of its shares through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In related news, EVP Michael Feld sold 165 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,907 shares of company stock worth $1,269,128 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BDX. Maryland Capital Advisors Inc. grew its position in shares of Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 139 shares in the last quarter. Trifecta Capital Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 59.0% in the third quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 62 shares during the period. Meeder Asset Management Inc. raised its position in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares in the last quarter. Main Street Group LTD purchased a new stake in shares of Becton, Dickinson and Company in the first quarter worth $29,000. Finally, Bell Investment Advisors Inc bought a new stake in Becton, Dickinson and Company during the second quarter valued at $29,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.